As per the terms of the agreement, Pepscan will increase the potency and stability of Mercator’s Homing Peptides and license to Mercator the associated intellectual property rights.
Pepscan is entitled to get undisclosed milestones, royalties and research funding from Mercator related to the development of optimized Homing Peptides and the development and commercialization of PDC products that couple optimized Homing Peptides with tumor-killing payloads.
Mercator chairman and CSO Roy Lobb said that Pepscan’s approach to peptide optimization is unique, systematic, fast, and efficient, and it provides Mercator with an opportunity to move its peptide-drug conjugates (PDCs) into development.